DOCSLIB.ORG

Aldrin Y Dieldrin Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Aldrin Y Dieldrin Pdf Aldrin y dieldrin pdf Continue Dieldrin Names IUPAC name (1aR,2R,2aS,3S,6R,6aR,7S,7aS)-3,4,5,6,9,9-hexachloro-1a,2,2a,3,6,6a,7,7a-octahydro-2,7:3,6-dimethanonaphtho[2,3-b]oxirene Other names Dieldrin, HEOD Identifiers CAS Number 60-57-1 Y 3D model (JSmol) Interactive image ChEBI CHEBI:34696 Y ChEMBL ChEMBL481118 N ChemSpider 10292746 Y ECHA InfoCard 100.000.440 KEGG C13718 Y PubChem CID 969491 UNII I0246D2ZS0 Y CompTox Dashboard (EPA) DTXSID9020453 InChI InChI=1S/C12H8Cl6O/c13-8-9(14)11(16)5-3-1-2(6-7(3)19-6)4(5)10(8,15)12(11,17)18/h2-7H,1H2/t2-,3+,4+,5-,6-,7+,10+,11- YKey: DFBKLUNHFCTMDC-PICURKEMSA-N YInChI=1/C12H8Cl6O/c13-8-9(14)11(16)5-3-1-2(6-7(3)19-6)4(5)10(8,15)12(11,17)18/h2-7H,1H2/t2- ,3+,4+,5-,6-,7+,10+,11-Key : DFBKLUNHFCTMDC-PICURKEMBL SMILES ClC5 (C@ C@@H C@H C@@H C@H C@H C@H Cl C@@)34 Properties Chemical Formula C12H8Cl6O Molar mass 380.91 g/mole Appearance colorless to light tanning crystals Density 1 ,75 g/cm3 Floating point 176 to 177 degrees Celsius (349 to 351 degrees Fahrenheit; 449 to 450 K) Boiling point 385 degrees Celsius (725 degrees Fahrenheit; 658 k) Solubility in water 0.02% 1 Dangers Of potential carcinogen 1 noncombustible outbreak point 1 Lethal dose or concentration (LD, LC): LD50 (medium dose) 45 mg/kg (oral, rabbit)49 mg/kg (oral, guinea pig)38 mg/kg (oral, mice)65 mg/kg (oral, dog)38 mg/kg (oral, rats) , 4 hours)13 mg/m3 (rat, 4 hours) (restrictions on health effects in the U.S.) : PEL (permissible) TWA 0.25 mg/m3 (skin) REL (Recommended) Ca TWA 0.25 mg/m3 (skin) IDLH (immediate danger) Ca data are given for materials in their standard condition (at 25 degrees Celsius, 100 kPa). N check (what is YN?) Infobox reference Dieldrin is an organochloride originally produced in 1948 by J. and Co., Denver, as an insecticide. Dieldrin is closely related to aldrin, which reacts further to form a dieldrin. Aldrin is not toxic to insects; It oxidizes in the insect to form dildrin, which is an active compound. Both dieldrin and aldrin are named after the Diels-Alder reaction which is used to form aldrin from the norbornadiene and hexachlorocyclocyclopentadiene. Originally developed in the 1940s as an alternative to DDT, dildrin was a highly effective insecticide and was widely used in the 1950s and early 1970s. Endrin is a stereoisomer dildrin. However, it is an extremely persistent organic pollutant; It's not easy to break. In addition, it tends to bio-recognize as it is transmitted across the food chain. Long-term exposure has proved toxic to a very wide range of animals, including humans, much more than for the original purpose of insects. For this reason, it is currently banned in most countries of the world. This was due to health problems such as Parkinson's disease, breast cancer, and immune, reproductive and nervous system damage. It is also an endocrine endocrine acting as estrogen and antiandrogen, and can negatively affect the origin of the testicles in the fetus if the pregnant woman is exposed to it. Dildrin synthesis can be formed from the Diels-Alder hexagonal-1.3-cyclocentadien reaction with norbornadien followed by epoxy of the addition of a product with pecoxic acid, such as paracetic acid, as shown below. Synthesis dieldrin Legislation and history Chemicals dieldrin and aldrin have been widely applied in agricultural areas around the world. Both are toxic and bioaccumative. Aldrin does break down into dildrin in living systems, but dildrin is known to resist bacterial and chemical decay processes in the environment. Aldrin was used to control soil pests (namely termites) on corn and potato crops. Dildrin was an insecticide used on fruits, soil and seeds. It persists in soil from half-seven years in temperate latitudes. Both aldrin and dildrin can be volatileed from sediments and redistributed by air currents, polluting areas far from their sources. They have been measured in the wild in the Arctic, indicating long-term transport from southern agricultural regions. Both aldrin and dildrin have been banned in most developed countries, but aldrin is still used as a term in Malaysia, Thailand, Venezuela and parts of Africa. In Canada, their sales were limited in the mid-1970s, with the last recorded use of compounds in Canada being seized in 1984. IPCS quotes the World Health Organization as saying that dildrin is banned for use in agriculture, particularly in Brazil, Ecuador, Finland, the German Democratic Republic, Singapore, Sweden, Yugoslavia and the USSR. European Community law prohibits the sale of phytopharmaceutical products containing dildrin. In Argentina, Canada, Chile, Germany, Hungary and the United States, its use is prohibited, with some exceptions. The use of dildrin is limited in India, Mauritius, Togo and the United Kingdom. Its use in industry is prohibited in Switzerland, and its production and use in Japan is under the control of the government. In Finland, the only common use of dildrin is a termicidide in a single adhesive mixture for exported plywood. India requires registration and licenses for all imports, production, sale or storage. Australia This section does not refer to any sources. Please help improve this section by adding links to reliable sources. Non-sources of materials can be challenged and removed. Find sources: Dildrin - News newspaper book scientist JSTOR (June 2018) (Learn how and when to remove this template message) Organochlorins and other chemicals were originally in the 1930s for use as an insecticide and pesticide. DDT became famous worldwide in 1939 after its use in overcoming typhoid in Naples. Use of organochlorin organochlorin in the 1950s and peaked in the 1970s. Their use in Australia was drastically reduced between the mid-1970s and the early 1980s. The first restrictions on the use of dildrin and related chemicals in Australia were introduced in 1961-2, and registration was required for their use in the production of animals such as cattle and chickens. This coincided with growing concern around the world about the long-term effects of persistent pesticides. The publication of Silent Spring (the report on the impact of pesticides on the environment and health) by Rachel Carson in 1962 was one of the key drivers in raising this concern. The phased phased phased withdrawal process was conditioned by government bans and deregistration, which in turn helped to change the public perception that food containing residues of these chemicals was less acceptable and possibly hazardous to health. Throughout this time, the relevant committees, such as the Technical Committee on Agricultural Chemicals (TCAC), have maintained constant pressure to reduce the approved use of organochlorin. By 1981, the use of dildrin worldwide was limited to sugar cane and bananas, and by 1985 these uses had been deregistered. A nationwide recall system was introduced in 1987, and in December of that year the Government banned all imports of these chemicals to Australia without the explicit approval of the Ministry. In 1994, the National Office for the Registration of Agricultural and Veterinary Chemicals published information on the use of organochlorins in termite control, recommending the phased abandonment of organochlorins used in termite control in the development of viable alternatives. In the same year, the Council for Agriculture and Resource Management of Australia and New York decided by 30 June 1995 to phase out organochlorin, with the exception of the Northern Territory. In November 1997, all organochlorin except mirex was discontinued in Australia. The remaining mirex reserves will only be used for termite baits on young tree plantations in the Northern Territory until stocks are released, which is expected in the near future. Recognition of the negative health impacts has spurred numerous legislative measures to use and remove organochloric pesticides. For example, the 1994 Environmental (Marine) Policy was introduced in South Australia in May 1995. He dictated an acceptable concentration of toxic substances such as dildrin in seawater, and how these levels should be tested and Momentum against organochlorin and similar molecules continued to grow internationally, leading to negotiations that have matured as the Stockholm Convention on the Use of Persistent Organic Pollutants (POPs). POPs are defined as dangerous and environmentally resistant substances that can be transported between countries by the oceans and the Earth's atmosphere. Land. POPs (including dildrin) bioaccumulate in fat tissues of humans and other animals. The Stockholm Convention banned 12 POPs dubbed the dirty dozen. These include: aldicarb, toxafen, chlordan and heptachlor, chlordimetform, chlorobenzilate, DBCP, DDT, drin (aldrin, dildrin and endrin), EDB, HCH and lindane, paraquat, parathion and methyl parathion, pentachlorofenol, and 2.4.5-T. It came into force on May 17, 2004. Australia ratified the Convention only three days later and became a party in August of that year. Long before that, Australia had made significant progress in taking action agreed upon under the Convention. Production, import and use of aldrin, chlordane, DDT, dildrin, hexachlorbenzene (HCB), heptachlor, endrin and toxaphene are prohibited in Australia. Production and importation of polychlorinated biphenyls (PCCs) are prohibited in Australia, with the phased cessation of existing PCDs managed in accordance with the National Strategy for the Treatment of Planned Waste. The strategy also explores how Australia will manage HCB waste and organochlorins. Australian legislation relating to the import, use and removal of dildrin and other organochlorins has been extensive and mainly covers environmental and potential health effects. Links to b c d e f NIOSH Pocket Guide on Chemical Hazards.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0070488A1 Coelingh Bennik Et Al
    US 2005.0070488A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0070488A1 Coelingh Bennik et al. (43) Pub. Date: Mar. 31, 2005 (54) ESTROGENIC COMPOUNDS IN prises the oral administration of an estrogenic component COMBINATION WITH PROGESTOGENIC and a progestogenic component to a mammal in an effective COMPOUNDS IN amount to prevent or treat Symptoms of hypoestrogenism, HORMONE-REPLACEMENT THERAPY wherein the estrogenic component is Selected from the group (76) Inventors: Herman Jan Tijmen Coelingh Bennik, consisting of Substances represented by the above formula in Driebergen (NL); Evert Johannes which formula R, R2, R, R independently are a hydrogen Bunschoten, Heesch (NL); Christian atom, a hydroxyl group or an alkoxy group with 1-5 carbon Franz Holinka, New York, NY (US) atoms; each of Rs, R, R-7 is a hydroxyl group; and no more than 3 of R, R2, R, R are hydrogen atoms; precursors Correspondence Address: capable of liberating a Substance according to the aforemen William Logsdon tioned formula when used in the present method; and Webb Ziesenheim Logsdon Orkin & Hanson mixtures of one or more of the aforementioned Substances 700 Koppers Building and/or precursors. Another aspect of the invention concerns 436 Seventh Avenue a pharmaceutical kit comprising oral dosage units that Pittsburgh, PA 15219-1818 (US) contain the aforementioned estrogenic component and a (21) Appl. No.: 10/495,707 progestogenic component as well as an androgenic compo nent. (22) PCT Filed: May 23, 2002 (86) PCT No.: PCT/NL02/00332 (30) Foreign Application Priority Data Nov. 15, 2001 (EP)........................................ O1204377.4 Feb.
    [Show full text]
  • Journal Pre-Proof
    Journal Pre-proof Steroid hormones in the aquatic environment J.O. Ojoghoro, M.D. Scrimshaw, J.P. Sumpter PII: S0048-9697(21)03377-5 DOI: https://doi.org/10.1016/j.scitotenv.2021.148306 Reference: STOTEN 148306 To appear in: Science of the Total Environment Received date: 19 April 2021 Revised date: 3 June 2021 Accepted date: 3 June 2021 Please cite this article as: J.O. Ojoghoro, M.D. Scrimshaw and J.P. Sumpter, Steroid hormones in the aquatic environment, Science of the Total Environment (2018), https://doi.org/10.1016/j.scitotenv.2021.148306 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2018 © 2021 Published by Elsevier B.V. Journal Pre-proof Steroid Hormones in the Aquatic Environment Ojoghoro, J.O.a, Scrimshaw, M.D.b* and Sumpter, J.P.b a Department of Botany, Faculty of Science, Delta State University Abraka, Delta State, Nigeria b Division of Environmental Science, Department of Life Sciences, Brunel University London, Uxbridge, Middlesex, UB8 3PH, United Kingdom Abstract Steroid hormones are extremely important natural hormones in all vertebrates.
    [Show full text]
  • Fee-For-Service Preferred Drug List
    Prescription Drug Program Apple Health Medicaid: Fee-for-Service Preferred Drug List What is new in this version of the preferred drug list? Effective for dates of service on and after October 1, 2018, the Health Care Authority will make the following changes: Change Due to the implementation of the Apple Health Preferred Drug List (PDL), a PDL that applies to fee-for-service (FFS) clients as well as Apple Health managed care enrollees, the following changes have occurred: On the Fee-For-Service only Preferred Drug List • Drug classes that are currently on the Apple Health PDL have been removed. These classes and the drug statuses can be found on the Apple Health Preferred Drug List. On the Apple Health Preferred Drug List • New drug classes have been added. This means drugs not previously on the PDL have been added with preferred and nonpreferred statuses. Some drugs may also have additional prior authorization (PA) requirements. • For existing drug classes, preferred statuses may have changed. Some drugs may have additional PA requirements that did not previously require PA. October 25, 2018 Correction • Two drug classes were erroneously removed and have been added back to the list: Asthma – Leukotriene Modifiers Skeletal Muscle Relaxants (Rev. 10/24/2018) (Eff. 10/1/2018) – 1 – Apple Health Medicaid PDL Prescription Drug Program What is the preferred drug list? The Health Care Authority (the agency) has developed a list of preferred drugs within a chosen therapeutic class that are selected based on clinical evidence of safety, efficacy, and effectiveness. The drugs within a chosen therapeutic class are evaluated by the Drug Use Review Board, which makes recommendations to the agency regarding the selection of the preferred drugs.
    [Show full text]
  • Progesterone 7K77 49-3265/R3 B7K770 Read Highlighted Changes Revised April, 2010 Progesterone
    en system Progesterone 7K77 49-3265/R3 B7K770 Read Highlighted Changes Revised April, 2010 Progesterone Customer Service: Contact your local representative or find country specific contact information on www.abbottdiagnostics.com Package insert instructions must be carefully followed. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in this package insert. Key to symbols used List Number Calibrator (1,2) In Vitro Diagnostic Medical Control Low, Medium, High Device (L, M, H) Lot Number Reagent Lot Expiration Date Reaction Vessels Serial Number Sample Cups Septum Store at 2-8°C Replacement Caps Consult instructions for use Warning: May cause an allergic reaction Contains sodium azide. Contact Manufacturer with acids liberates very toxic gas. See REAGENTS section for a full explanation of symbols used in reagent component naming. 1 NAME REAGENTS ARCHITECT Progesterone Reagent Kit, 100 Tests INTENDED USE NOTE: Some kit sizes are not available in all countries or for use on all ARCHITECT i Systems. Please contact your local distributor. The ARCHITECT Progesterone assay is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of progesterone in ARCHITECT Progesterone Reagent Kit (7K77) human serum and plasma. • 1 or 4 Bottle(s) (6.6 mL) Anti-fluorescein (mouse, monoclonal) fluorescein progesterone complex coated Microparticles SUMMARY AND EXPLANATION OF TEST in TRIS buffer with protein (bovine and murine) and surfactant Progesterone is produced primarily by the corpus luteum of the ovary stabilizers. Concentration: 0.1% solids. Preservatives: sodium azide in normally menstruating women and to a lesser extent by the adrenal and ProClin. cortex.1 At approximately the 6th week of pregnancy, the placenta 2-5 • 1 or 4 Bottle(s) (17.0 mL) Anti-progesterone (sheep, becomes the major producer of progesterone.
    [Show full text]
  • Not for Publication United States District Court For
    Case 3:10-cv-00603-PGS-DEA Document 289 Filed 06/29/12 Page 1 of 47 PageID: <pageID> NOT FOR PUBLICATION UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY TEVA WOMEN’S HEALTH, INC., Civil Action No.: Plaintiff, 10-603 (PGS) v. OPINION LUPIN, LTD. et al., Defendants. SHERIDAN, U.S.D.J. This case is a patent infringement action arising under the Hatch-Waxman Act involving Teva Women’s Health, Inc.’s (Teva) oral contraceptive (OC) Seasonique.1 Teva owns the patent-in-suit, U.S. Patent No. 7,320,969 (“the ’969 patent”). The ’969 patent, entitled “Oral contraceptives to prevent pregnancy and diminish premenstrual symptomology,” was issued on January 22, 2008. Teva’s predecessors-in-interest to the ’969 patent include Duramed and Barr.2 Teva alleges that defendants Lupin Ltd. and Lupin Pharmaceuticals, Inc. (collectively, “Lupin”) and defendants Mylan Inc., Mylan Pharmaceuticals, Inc., and Famy Care Ltd. (collectively, “Mylan”) infringed on Claim 19 of the ’969 patent. Claim 19 of the ’969 patent discloses an extended OC regimen that administers unopposed estrogen during the traditionally hormone free 1 While Seasonique and similar FDA-approved products are trademarked, in this opinion the Court refrains from using such marks for the sake convenience. 2 There is a lawsuit captioned Duramed Pharmaceuticals v. Watson Laboratories, Case No. 08-116 (D. Nev.) which involves the same patent and remains pending in Nevada. Although the parties knew of this other case, none of the parties sought to consolidate matters. Case 3:10-cv-00603-PGS-DEA Document 289 Filed 06/29/12 Page 2 of 47 PageID: <pageID> interval (HFI).
    [Show full text]
  • Steroidal Estrogens
    FINAL Report on Carcinogens Background Document for Steroidal Estrogens December 13 - 14, 2000 Meeting of the NTP Board of Scientific Counselors Report on Carcinogens Subcommittee Prepared for the: U.S. Department of Health and Human Services Public Health Service National Toxicology Program Research Triangle Park, NC 27709 Prepared by: Technology Planning and Management Corporation Canterbury Hall, Suite 310 4815 Emperor Blvd Durham, NC 27703 Contract Number N01-ES-85421 Dec. 2000 RoC Background Document for Steroidal Estrogens Do not quote or cite Criteria for Listing Agents, Substances or Mixtures in the Report on Carcinogens U.S. Department of Health and Human Services National Toxicology Program Known to be Human Carcinogens: There is sufficient evidence of carcinogenicity from studies in humans, which indicates a causal relationship between exposure to the agent, substance or mixture and human cancer. Reasonably Anticipated to be Human Carcinogens: There is limited evidence of carcinogenicity from studies in humans which indicates that causal interpretation is credible but that alternative explanations such as chance, bias or confounding factors could not adequately be excluded; or There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors: (1) in multiple species, or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site or type of tumor or age at onset; or There is less than sufficient evidence of carcinogenicity in humans or laboratory animals, however; the agent, substance or mixture belongs to a well defined, structurally-related class of substances whose members are listed in a previous Report on Carcinogens as either a known to be human carcinogen, or reasonably anticipated to be human carcinogen or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.
    [Show full text]
  • Oregon's Medicaid
    kaiser commission on medicaid and the uninsured Oregon’s Medicaid PDL: Will an Evidence- Based Formulary with Voluntary Compliance Set a Precedent for Medicaid? Prepared by: Cathy Bernasek Dan Mendelson Ryan Padrez Catherine Harrington, PharmD The Health Strategies Consultancy LLC January 2004 kaiser commission medicaid and the uninsured The Kaiser Commission on Medicaid and the Uninsured provides information and analysis on health care coverage and access for the low-income population, with a special focus on Medicaid’s role and coverage of the uninsured. Begun in 1991 and based in the Kaiser Family Foundation’s Washington, DC office, the Commission is the largest operating program of the Foundation. The Commission’s work is conducted by Foundation staff under the guidance of a bi- partisan group of national leaders and experts in health care and public policy. James R. Tallon Chairman Diane Rowland, Sc.D. Executive Director Oregon’s Medicaid PDL: Will an Evidence- Based Formulary with Voluntary Compliance Set a Precedent for Medicaid? Prepared by: Cathy Bernasek Dan Mendelson Ryan Padrez Catherine Harrington, PharmD The Health Strategies Consultancy LLC January 2004 Table of Contents ABSTRACT……………………………………………………………………………...i EXECUTIVE SUMMARY…………………………………………………………….iii INTRODUCTION…………………………………………………………………….…1 BACKGROUND ON MEDICAID IN OREGON……………………………………..4 AUTHORIZATION OF OREGON’S PREFERRED DRUG LIST……………….…5 OREGON’S PRACTITIONER-MANAGED PRESCRIPTION DRUG PLAN…….7 PERSPECTIVES ON OREGON’S PRACTITIONER-MANAGED PRESCRIPTION DRUG PLAN……………………………………………….15
    [Show full text]
  • 3 Tier Copay 23 Therapeutic Categories Note: Non-Preferred Drugs Include All Forms of the Drugs
    3 Tier Copay 23 Therapeutic Categories Note: Non-preferred drugs include all forms of the drugs Therapeutic Categories Preferred drugs Non-Preferred Drugs Cholesterol Lowering Agents Lipitor (atorvastatin) Zocor (simvastatin) (HMG-CoA ) Pravachol (pravastatin) Mevacor* (lovastatin) Lescol (fluvastatin) Antidepressants – Celexa (citalopram) Remeron (mirtazapine) Selective Serotonin Reuptake Effexor (venlafaxine) Serzone (nefazodone) Inhibitors Effexor XR (venlafaxine) (SSRI) and newer non-SSRI Paxil (paroxetine) Wellbutrin* (bupropion) Wellbutrin SR (bupropion) Zoloft (sertraline) Prozac* (fluoxetine) Luvox (fluvoxamine) High Blood Pressure Agents – Accupril (quinapril) Aceon (perindopril erbumine ) Angiotension Converting Capoten* (captopril) Monopril (fosinopril) Enzyme Inhibitors (ACEI) Altace (ramipril) Lotensin (benazepril) Zestril (lisinopril) Mavik (trandolapril) Vasotec (enalapril) Prinivil (lisinopril) Univasc (moexipril) High Blood Pressure Agents – Cozaar (losartan) Atacand (candesartan) Angiotensin Receptor Hyzaar(losartan/hctz) Micardis (telmisartan) Blockers (ARB) Diovan (valsartan) Teveten (eprosartan mesylate) Diovan HCT (valsartan/hctz) Avapro (irbesartan) Avalide (irbesartan/hctz) Benicar (olmesartan) Pain Agents – Cataflam* (diclofenac) Bextra (valdecoxib) Non- Steroidal Anti- Daypro (oxaprozin) Vioxx (rofecoxib) inflammatory Drugs and Lodine XL* (etodolac) COX-2s Relafen (nabumetone) Celebrex (celecoxib) Toradol *(ketorolac) Voltaren *(diclofenac) Lodine *(etodolac) Ansaid *(flurbiprofen) Indocin* (indomethacin) Nalfon*
    [Show full text]
  • Estramustine Sodium Phosphate Capsules BP
    PRODUCT MONOGRAPH PrEMCYT* (estramustine sodium phosphate capsules B.P.) 140 mg/capsule Antineoplastic Pfizer Canada Inc Date of Revision: 17,300 Trans-Canada Highway 10 December 2015 Kirkland, Quebec H9J 2M5 Control No. 186447 * TM Pharmacia AB Pfizer Canada Inc, Licensee Pfizer Canada Inc 2015 1 PRODUCT MONOGRAPH NAME OF DRUG PrEMCYT Estramustine sodium phosphate capsules B.P. THERAPEUTIC CLASSIFICATION Antineoplastic CAUTION: EMCYT (ESTRAMUSTINE SODIUM PHOSPHATE) IS A POTENT DRUG AND SHOULD BE PRESCRIBED ONLY BY PHYSICIANS EXPERIENCED WITH CANCER CHEMOTHERAPEUTIC DRUGS (SEE WARNINGS & PRECAUTIONS). BLOOD COUNTS, AS WELL AS RENAL AND HEPATIC FUNCTION TESTS, SHOULD BE PERFORMED REGULARLY. DISCONTINUE THE DRUG IF ABNORMAL RENAL OR HEPATIC FUNCTION IS SEEN. CAPSULES SHOULD NOT BE OPENED. ACTION Emcyt (estramustine sodium phosphate) has a dual mode of action. The intact molecule acts as an anti-mitotic agent and after hydrolysis of the carbamate ester bridge the released estrogens exert an anti-gonadotrophic effect. The low level of clinically manifested side effects may be due to the fact that estramustine binds to a protein present in the tumor tissue, which results in an accumulation of the drug at the target site. 2 INDICATIONS The treatment of metastatic prostatic carcinoma (stage D) in patients whose disease is refractory to hormonal therapy. Emcyt (estramustine sodium phosphate) may produce either a stabilization or regression of the disease process and improvement in ability to function. CONTRAINDICATIONS Emcyt should not be used in patients with any of the following conditions: * known hypersensitivity to either estradiol or to nitrogen mustard * severe hepatic or cardiac disease * active thrombophlebitis or thromboembolic disorders WARNINGS Emcyt (estramustine sodium phosphate) should be used with caution in patients with a history of thrombophlebitis, thrombosis or thromboembolic disorders, especially if associated with estrogen therapy.
    [Show full text]
  • NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010
    NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational Safety and Health NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational Safety and Health This document is in the public domain and may be freely copied or reprinted. DISCLAIMER Mention of any company or product does not constitute endorsement by the National Institute for Occupational Safety and Health (NIOSH). In addition, citations to Web sites external to NIOSH do not constitute NIOSH endorsement of the sponsoring organizations or their programs or products. Furthermore, NIOSH is not responsible for the content of these Web sites. ORDERING INFORMATION To receive documents or other information about occupational safety and health topics, contact NIOSH at Telephone: 1–800–CDC–INFO (1–800–232–4636) TTY:1–888–232–6348 E-mail: [email protected] or visit the NIOSH Web site at www.cdc.gov/niosh For a monthly update on news at NIOSH, subscribe to NIOSH eNews by visiting www.cdc.gov/niosh/eNews. DHHS (NIOSH) Publication Number 2010−167 September 2010 Preamble: The National Institute for Occupational Safety and Health (NIOSH) Alert: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings was published in September 2004 (http://www.cdc.gov/niosh/docs/2004-165/). In Appendix A of the Alert, NIOSH identified a sample list of major hazardous drugs. The list was compiled from infor- mation provided by four institutions that have generated lists of hazardous drugs for their respec- tive facilities and by the Pharmaceutical Research and Manufacturers of America (PhRMA) from the American Hospital Formulary Service Drug Information (AHFS DI) monographs [ASHP/ AHFS DI 2003].
    [Show full text]
  • 2012 NIOSH List of Antineoplastic and Other Hazardous Drugs
    NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational Safety and Health NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational Safety and Health This document is in the public domain and may be freely copied or reprinted. Disclaimer Mention of any company or product does not constitute endorsement by the National Institute for Occupational Safety and Health (NIOSH). In addition, citations to Web sites external to NIOSH do not constitute NIOSH endorsement of the sponsoring organizations or their programs or products. Furthermore, NIOSH is not responsible for the content of these Web sites. Ordering Information To receive documents or other information about occupational safety and health topics, contact NIOSH at Telephone: 1–800–CDC–INFO (1–800–232–4636) TTY:1–888–232–6348 E-mail: [email protected] or visit the NIOSH Web site at www.cdc.gov/niosh For a monthly update on news at NIOSH, subscribe to NIOSH eNews by visiting www.cdc.gov/niosh/eNews. DHHS (NIOSH) Publication Number 2012−150 (Supersedes 2010–167) June 2012 Preamble: The National Institute for Occupational Safety and Health (NIOSH) Alert: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings was published in September 2004 (http://www.cdc.gov/niosh/docs/2004-165/). In Appendix A of the Alert, NIOSH identified a sample list of major hazardous drugs.
    [Show full text]
  • Appendix B - Product Name Sorted by Applicant
    JUNE 2021 - APPROVED DRUG PRODUCT LIST B - 1 APPENDIX B - PRODUCT NAME SORTED BY APPLICANT ** 3 ** 3D IMAGING DRUG * 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC AMMONIA N 13, AMMONIA N-13 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18 3M * 3M CO PERIDEX, CHLORHEXIDINE GLUCONATE * 3M HEALTH CARE INC AVAGARD, ALCOHOL (OTC) DURAPREP, IODINE POVACRYLEX (OTC) 3M HEALTH CARE * 3M HEALTH CARE INFECTION PREVENTION DIV SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC) ** 6 ** 60 DEGREES PHARMS * 60 DEGREES PHARMACEUTICALS LLC ARAKODA, TAFENOQUINE SUCCINATE ** A ** AAA USA INC * ADVANCED ACCELERATOR APPLICATIONS USA INC LUTATHERA, LUTETIUM DOTATATE LU-177 NETSPOT, GALLIUM DOTATATE GA-68 AAIPHARMA LLC * AAIPHARMA LLC AZASAN, AZATHIOPRINE ABBVIE * ABBVIE INC ANDROGEL, TESTOSTERONE CYCLOSPORINE, CYCLOSPORINE DEPAKOTE ER, DIVALPROEX SODIUM DEPAKOTE, DIVALPROEX SODIUM GENGRAF, CYCLOSPORINE K-TAB, POTASSIUM CHLORIDE KALETRA, LOPINAVIR NIASPAN, NIACIN NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE NIMBEX, CISATRACURIUM BESYLATE NORVIR, RITONAVIR SYNTHROID, LEVOTHYROXINE SODIUM ** TARKA, TRANDOLAPRIL TRICOR, FENOFIBRATE TRILIPIX, CHOLINE FENOFIBRATE ULTANE, SEVOFLURANE ZEMPLAR, PARICALCITOL ABBVIE ENDOCRINE * ABBVIE ENDOCRINE INC LUPANETA PACK, LEUPROLIDE ACETATE ABBVIE ENDOCRINE INC * ABBVIE ENDOCRINE INC LUPRON DEPOT, LEUPROLIDE ACETATE LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE ABBVIE INC * ABBVIE INC DUOPA, CARBIDOPA MAVYRET, GLECAPREVIR NORVIR, RITONAVIR ORIAHNN (COPACKAGED), ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
    [Show full text]